Navigation Links
YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
Date:10/29/2009

e American Society for Therapeutic Radiology and Oncology's Annual Meeting on November 2, 2009 reporting on 48 month survival data in "BEST", a randomized 4-arm trial of nimotuzumab with radiation and chemoradiation with patients with locally advanced head and neck cancer. Scientific Session D: Head and Neck I - Advances in Targeted Biologic Therapy, 11:20a.m., Room W184.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 5,000 patients reported as having been treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differen
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... ... technology are highlighted at leading industry events. , ... Washington, DC (PRWEB) June 11, 2010 -- Open source software will be ... DIA Annual Meeting is the premier event for professionals involved in the discovery, ...
... June 11 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ) ... products in China , today reported,its financial results for the ... , , 4Q10 Financial Highlights, ... year-over-year increase;, ...
... ... of the evolution of the influenza virus and its human host, post-graduate student Stephen Huff ... of safe, free software downloads - best of all, the service is free. , ... (PRWEB) June 5, 2010 -- We ...
Cached Biology Technology:Open Source Clinical Trials Software Featured at the 46th DIA Annual Meeting 2Open Source Clinical Trials Software Featured at the 46th DIA Annual Meeting 3China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 2China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 3China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 4China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 5China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 6China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 7China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 8China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 9China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 10China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 11China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 12China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 13China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 14China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 15China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 16Computational Microbiologist Uses His Expertise with Deadly Viruses to Devise a Superior System for Delivery of Safe, Free Software Downloads 2Computational Microbiologist Uses His Expertise with Deadly Viruses to Devise a Superior System for Delivery of Safe, Free Software Downloads 3Computational Microbiologist Uses His Expertise with Deadly Viruses to Devise a Superior System for Delivery of Safe, Free Software Downloads 4
(Date:10/19/2014)... access in India over the last 30 years ... emissions growth during that time, according to a ... Climate Change ., "Energy access is fundamental to ... life, including education, communication, and health," says IIASA ... While increased energy access is widely agreed to ...
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... – Accurate knowledge regarding Ebola is critical and pertinent ... of hazardous global outbreak and epidemic. The Journal, ... a special issue, Ebola Virus and Public Health, to ... knowledge in this critical societal moment. , On ... Ebola for Clinicians . The primer was prepared by ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Whole-exome sequencing shows potential as diagnostic tool 2
... Director of Genomic Technologies, Dr Yijun RUAN, led a ... how genes interact/communicate and influence each other, even when ... discovery is crucial in understanding how human genes work ... and coordination takes place in human cells. The ...
... Spotted salamanders exposed to contaminated roadside ponds are ... paper in Scientific Reports. This study provides the first ... negative effects of roads apparently by evolving rapidly. ... a host of contaminants from road runoff. Chief among ...
... The first study to check the effects of eating ... small helpings of purple potatoes (Purple Majesty) a day decreases ... In a report in the ACS, Journal of Agricultural ... seemingly small, is sufficient to potentially reduce the risk of ...
Cached Biology News:Singapore scientists lead in 3D mapping of human genome to help understand human diseases 2Road runoff spurring spotted salamander evolution 2
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
... Microarray Gene Frame® has been specifically ... frames feature the same dual strength ... Frame® range for easy removal after ... and there are three sizes available. ...
For microscopy...
... slide processing offering reproducibility, reliability and ... miniaturization, automation and massive parallel analysis ... with many applications in both industrial ... from gene expression profiling, gene regulation ...
Biology Products: